Relationship between prostate-specific antigen, age, and body mass index in a prostate cancer screening population

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 5, 2012, Pages 490-492

  Pater, Luke E ^a   Hart, Kimberly W ^b   Blonigen, Brian J ^a   Lindsell, Christopher J ^b   Barrett, William L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

BMI; prostate cancer; prostate cancer screening; PSA; PSA accepted normal value range

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; ASSOCIATION; BODY MASS; CANCER SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; OBSERVATIONAL STUDY; POPULATION; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ADULT; BODY COMPOSITION; BODY MASS INDEX; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OBESITY; OHIO; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84866651264     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31821a83be     Document Type: Article

References (17)

1. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2005 Incidence and Mortality Web-based Report. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2009. Available at: www.cdc.gov/uscs.
2. Surveillance Epidemiology, and End Results (SEER) Program. Released April 2009, based on the November 2008 submission. http://www.seer.cancer.gov, accessed January 15, 2010.
3. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
4. Schroder FH, Hugosson J, Roobol MJ, et al ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
5. Lu-Yao G, Albertsen PC, Stanford JL, et al. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut. J Gen Intern Med. 2008;23:1809-1814.
6. Esserman L, Yiweh S, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302:1685-1692.
7. Culp S, Porter M. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. BJUI. 2009;104:1457-1461.
8. Werny DM, Thompson T, Saraiya M, et al. Obesity is negatively associated with prostate-specific antigen in US men, 2001-2004. Cancer Epidemiol Biomarkers Prev. 2007;16:70-76.
9. Rundle A, Richards C, Neugut A. Body composition, abdominal fat distribution, and prostate-specific antigen test results. Cancer Epidemiol Biomarkers Prev. 2009;18:331-336.
10. Muller H, Raum E, Rothenbacher D, et al. Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev. 2009;18:1350-1356.
11. Bañez LL, Hamilton RJ, Partin AW, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007;298:2275-2280.
12. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005;103:1092-1095.
13. Han JH, Chang IH, Ahn SH, et al. Association between serum prostate-specific antigen level, liver function tests and lipid profile in healthy men. BJUI. 2008;102:1097-1101.
14. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-241.
15. Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22:446-453.
16. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in med with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439-445.
17. Bañez LL, Sun L, Trock BJ, et al. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009;182:491-496.